Niagen Bioscience (NAGE) Stock Price, News & Analysis

Company Overview

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Key Stats

• Today's Range: $9.69 to $10.28
• 50-Day Range: $9.04 to $11.50
• 52-Week Range: $3.18 to $14.69
• Volume: 799,838 shs
• Average Volume: 938,369 shs
• Market Capitalization: $817.44 million
• P/E Ratio: 48.81
• Dividend Yield: N/A
• Price Target: $13.42
• Consensus Rating: Buy

Niagen Bioscience Stock Analysis - MarketRank™

Niagen Bioscience scored higher than 32% of companies evaluated by MarketBeat, and ranked 769th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Niagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Niagen Bioscience has a consensus price target of $13.42, representing about 34.9% upside from its current price of $9.95.

Amount of Analyst Coverage

Niagen Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Niagen Bioscience is 47.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 298.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Niagen Bioscience is 47.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 350.66.

Price to Book Value per Share Ratio

Niagen Bioscience has a P/B Ratio of 16.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.44% of the float of Niagen Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Niagen Bioscience has a short interest ratio ("days to cover") of 4.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Niagen Bioscience does not currently pay a dividend.

Dividend Growth

Niagen Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.44% of the float of Niagen Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Niagen Bioscience has a short interest ratio ("days to cover") of 4.

Change versus previous month

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Niagen Bioscience this week, compared to 3 articles on an average week.

Search Interest

22 people have searched for NAGE on MarketBeat in the last 30 days. This is an increase of 633% compared to the previous 30 days.

MarketBeat Follows

4 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Niagen Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.39% of the stock of Niagen Bioscience is held by insiders.

Percentage Held by Institutions

Only 15.41% of the stock of Niagen Bioscience is held by institutions.

NAGE Stock Analysis - Frequently Asked Questions

How have NAGE shares performed this year?

Niagen Bioscience's stock was trading at $5.48 on January 1st, 2025. Since then, NAGE shares have increased by 81.6% and is now trading at $9.95.

How were Niagen Bioscience's earnings last quarter?

Niagen Bioscience, Inc. (NASDAQ:NAGE) posted its quarterly earnings data on Wednesday, August, 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The company had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a trailing twelve-month return on equity of 23.12% and a net margin of 15.24%.

How do I buy shares of Niagen Bioscience?

Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NAGE
• Previous Symbol: NASDAQ:NAGE
• CIK: 1386570
• Web: N/A
• Phone: (310) 388-6706
• Fax: 949-419-0294
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Niagen Bioscience: $13.42
• High Price Target: $23.00
• Low Price Target: $8.00
• Potential Upside/Downside: +30.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: 48.81
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8.55 million
• Net Margins: 15.24%
• Pretax Margin: 15.76%
• Return on Equity: 23.12%
• Return on Assets: 15.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.88
• Quick Ratio: 3.24

Sales & Book Value

• Annual Sales: $99.60 million
• Price / Sales: 8.21
• Cash Flow: $0.06 per share
• Price / Cash Flow: 166.70
• Book Value: $0.60 per share
• Price / Book: 17.08

Miscellaneous

• Outstanding Shares: 79,750,000
• Free Float: 72,264,000
• Market Cap: $817.44 million
• Optionable: N/A
• Beta: 2.22